-
AstraZeneca, Daiichi Sankyo obtain FDA nod for Datroway
02 Jul 2025 19:07 GMT
… oncology business, and president and CEO, Daiichi Sankyo, said, “With today’s accelerated …
-
AstraZeneca-Daiichi Sankyo Datroway gets USFDA accelerated nod for previously treated advanced EGFR-mutated non-small cell lung cancer
26 Jun 2025 07:23 GMT
… Business, and President and CEO, Daiichi Sankyo, Inc, said, “ … ADC) discovered by Daiichi Sankyo and being jointly developed … AstraZeneca and Daiichi Sankyo.
AstraZeneca and Daiichi Sankyo are evaluating … ADC. Designed using Daiichi Sankyo’s proprietary DXd …
-
AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC
25 Jun 2025 03:46 GMT
… , and president and CEO, Daiichi Sankyo, Inc, said: … AstraZeneca and Daiichi Sankyo.
AstraZeneca and Daiichi Sankyo are … Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo … Datroway in collaboration Daiichi Sankyo; Orpathys (savolitinib) …
-
Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch'
28 Apr 2025 22:23 GMT
… antibody-drug conjugate launched by Daiichi Sankyo and AstraZeneca, Datroway has a … a “smooth market launch,” Daiichi CEO Hiroyuki Okuzawa said on a …
-
European Union approves Daiichi Sankyo & AstraZeneca's Datroway to treat patients with metastatic hormone receptor positive and HER2 negative breast cancer
10 Apr 2025 04:14 GMT
… , and president and CEO, Daiichi Sankyo, Inc.
“Datroway … in various settings.
Daiichi Sankyo and AstraZeneca entered … Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo … developed by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform …
-
AstraZeneca & Daiichi Sankyo’s Enhertu gets EU approval to treat patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy
05 Apr 2025 04:50 GMT
… business, and president and CEO, Daiichi Sankyo, said: “Enhertu … underway.
AstraZeneca and Daiichi Sankyo entered into a … Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo … Enhertu, AstraZeneca and Daiichi Sankyo are aiming to improve …
-
Daiichi Sankyo aims to launch 5 ADC therapies in Korea by 2030
26 Mar 2025 07:50 GMT
Daiichi Sankyo Korea has unveiled … proprietary DXd-ADC platform,” Daiichi Sankyo Korea CEO Kim Jeong-tae said. … the ADC World Awards,” Daiichi Sankyo Korea Oncology Medical Unit … “Expand & Extend” strategy, Daiichi Sankyo aims to broaden ADC indications …
-
Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance Delveinsight
04 Mar 2025 23:38 GMT
… another Japanese Pharmaceutical company, Daiichi Sankyo, in the TGCT market. … targeted therapy developed by Daiichi Sankyo for adult patients … fellow Japanese pharmaceutical company Daiichi Sankyo in the TGCT space … time, Ono's CEO, Gyo Sagara, described …
-
Daiichi Sankyo Appoints Chief Executive Officer
31 Jan 2025 20:07 GMT
… , DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025.
Dr … resources during his tenure at Daiichi Sankyo. Mr. Okuzawa graduated from Hitotsubashi … honored to be the next CEO of Daiichi Sankyo and will follow Sunao …
-
Daiichi Sankyo taps new CEO, aims to build up ADC franchise
31 Jan 2025 16:26 GMT
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over …
About
© 1995-2025